Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

Clinical trial NCT04107142 · UNKNOWN

Trial details

NCT number: NCT04107142
Sponsor: CytoMed Therapeutics Pte Ltd
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Colorectal Cancer Triple Negative Breast Cancer Sarcoma Nasopharyngeal Carcinoma Prostate Cancer Gastric Cancer

Start date: 2019-12-01
Primary completion: 2020-09-01
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.